MIMEDX to Host Fourth Quarter 2021 Operating and Financial Results Conference Call on February 28
MiMedx Group, Inc. (MDXG) will release its financial results for Q4 2021 on February 28, 2022, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MiMedx Group, Inc. (MDXG) will release its financial results for Q4 2021 on February 28, 2022, after market close. A webcast and conference call will follow at 5:00 p.m. ET for management to discuss these results. The company specializes in placental biologics, providing allografts for treating acute and chronic wounds, and has a strong pipeline for musculoskeletal conditions. With over 2 million allografts supplied, MiMedx focuses on innovative healthcare solutions.
Positive
- Strong pipeline targeting degenerative musculoskeletal conditions.
- Over 2 million allografts supplied, showcasing market presence.
Negative
- None.
Details
News Market Reaction – MDXG
The recorded move for MDXG in the trading session of this news was -2.35%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MARIETTA, Ga., Feb. 14, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report operating and financial results for the fourth quarter ended December 31, 2021 after the market close on Monday, February 28, 2022. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 5:00 p.m. Eastern Time on the same day.
The conference call can be accessed using the following information:
Webcast: Click here
U.S. Investors: 877-407-6184
International Investors: 201-389-0877
Conference ID: 13726222
A replay of the webcast will be available for approximately 30 days on the Company’s website at www.mimedx.com following the conclusion of the event.
About MIMEDX
MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental tissue engineering, we have both a commercial business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.
Contacts:
Investors
Jack Howarth
404-360-5681
jhowarth@mimedx.com
Corporate Communications
Hilary Dixon
404-323-4779
hdixon@mimedx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.